Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...

周四，Piper Sandler调整了对Abbott Laboratories (NYSE:ABT)的展望，将目标价从之前的131美元上调至133美元，同时维持对该股票的增持评级。 这一变化是在Abbott公布第三季度业绩后做出的。该季度业绩超出了华尔街对收入和调整后每股收益(EPS)的预期，尽管其基本面收入增长略低于预期。 Abbott的医疗技术业务在第三季度表现出强劲增长，这有助于平衡营养和诊 ...

Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...

Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...

The Searle Company Limited (PSX: SEARL) has denied showing any interest in acquiring a 51 percent stake in Abbott ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

Abbott Laboratories (NYSE: ABT)公布了强劲的第三季度业绩,有机销售增长超过8%,调整后每股收益为1.21美元。该公司2023年第三次上调全年指引,称强劲的设备销售是主要驱动因素。 Abbott ...

Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...